- Product
- Why Tagrisso and Opdivo failed reimbursement expansions
- by Moon, sung-ho Dec 6, 2021 05:53am
- The 3rd generation targeted therapy for lung cancer, ‘Tagrisso (osimertinib)’ once again failed to expand reimbursement to first-line treatment. The reason was that the drug was more appropriate as a second-line treatment in terms of cost-effectiveness. By failing to expand reimbursement at the last Cancer Drug Review Committee meeting held
- Product
- Organon aims to resume Cozaar XQ supply from 2022 Q1
- by Nov 25, 2021 05:56am
- 'Cozaar XQ,' an antihypertensive combination drug that contains losartan, may be resupplied to pharmacies within the first quarter of next year, at the earliest. The company had made preparations to change the API source of Cozaar XQ to be the same as the one for Cozaar, which uses a losartan API from a different overseas manufacturer (Fr
- Product
- α-GPC can't be replaced with other drugs in the field
- by Kim, Jin-Gu Nov 25, 2021 05:55am
- Apart from the steady increase in the number of patients over the past 20 years, there has been no significant change in dementia treatments used in Clinic sites. However, two major changes have been predicted in the past two years. One is the controversy over the preparation of Choline alfoscerate in Korea, and the other is the controversy surr
- Product
- AstraZeneca vaccination is expected to end as of this year
- by Nov 24, 2021 05:53am
- The first inoculation will end at the end of November, and for the second inoculation, all inoculations will end on the 31st of next month. Medical institutions that have AstraZeneca vaccines should provide primary vaccinations with vaccines they have, and inform the inoculated that secondary vaccinations should be cross-vaccinated with Pf
- Product
- Expansion of non-face-to-face tx little by little
- by Nov 18, 2021 05:54am
- Despite opposition from the KMA to expand non-face-to-face treatment using regulatory sandboxes, it is judged that the satisfaction of overseas Koreans is high and it will help resolve medical blind spots. However, concerns about allowing regulatory special cases are also expected to increase, taking advantage of regulatory sandboxes. Mini
- Product
- Claiming a more expensive drug than a generic
- by Kim JiEun Nov 11, 2021 06:00am
- Pharmacist A, who did not give a follow-up notice of general submission and charged for a drug that was more expensive than an alternative drug, filed a lawsuit claiming that it was an unfair disposition, but the court refused to accept it. The Seoul Northern District Court recently dismissed a claim filed by pharmacist A against the NHIS
- Product
- PO treatment for COVID-19 "Molnupiravir" will be released
- by Whang, byung-woo Oct 29, 2021 05:53am
- The emergence of Molnupiravir of MSD, known as the first oral treatment for COVID-19, is drawing attention to how it will affect the war against COVID-19. While it is compared to Tamiflu and is evaluated as a game changer, there are mixed views on the other side that its role may be limited due to price limitations. According to the interim
- Product
- Smoking cessation tx, sold out due to impurities
- by Kim JiEun Oct 1, 2021 06:08am
- According to local pharmacies on the 1st, most Bupropions used for smoking cessation treatment are sold out or lack of inventory, making it difficult to order at online malls. This out of stock is related to the recent controversy over the detection of impurities in the Varenicline. As NNV, a carcinogen, was detected in Champix (Vareniclin
- Product
- Take Ibuprofen after Pfizer COVID vaccine??
- by Kim JiEun Sep 6, 2021 05:58am
- Following Tylenol, the purchase of related drugs is increasing as Ibuprofen-containing painkillers have been raised to prevent side effects of COVID vaccines in certain companies. According to outpatient pharmacies on the 6th, patients who have recently been vaccinated (Pfizer vaccines) have frequently sought Ibuprofen-containing anti-infl
- Product
- Disturbance to secure inventory of Diovan and Exforge
- by Jung, Heung-Jun Sep 5, 2021 08:26pm
- Pharmacists suffered from inventory after six products, including Diovan and Exforge, by Novartis Korea, were announced to local pharmacies on the afternoon of the 1st. When there were concerns that impurities were detected, Novartis Korea explained that the quality was fine, but it was a lot release that was decided due to administrative del
